Virasoft is participating in a joint-project to develop machine learning-based diagnostic tool against Breast Cancer
ISTANBUL, August 26, 2022 – Breast cancer is an urgent worldwide issue in fact the burden this global problem is increasing. Early diagnosis is the most important parameter for breast cancer as it is for the other progressive diseases. Moreover, limited access to healthcare and adequate resources requires multidisciplinary approach to manage breast cancer cases.
At Virasoft, we launched a project to build a machine learning model for breast cancer diagnosis featuring oncological treatment methodologies. The collaborative project among 4 countries including Belgium, Slovenia, Spain and Turkey, aims to aid physicians in decision making process for patient care with AI-powered algorithms on reliable outcomes. ITEA project called HeKDisco : Healthcare Knowledge Discovery promises reduced clinical errors, precise early diagnosis, more accessible individual patient care and therapeutic outcome prediction.
###
About Virasoft
Virasoft is a technology startup, focused on AI-powered decision support algorithms, digital pathology workflow solutions, telepathology systems and educational tools for pathologists and pathology laboratories. Virasoft is headquartered in New York with offices in Istanbul, Turkey. Broad-based spectrum of services enables accessing and curating data for the development of the deep learning algorithms.
Hospital Manager Magazine, which started its publication life in 2008 with the aim of being a special magazine for contemporary healthcare managers...
Virasoft is pleased to announced that they will be a part of the USCAP Annual conference in Los Angeles as a Gold Level Sponsor.
Virasoft is proud to announce that once again entitled to the ISO27001 - Information Security Management System certificate.
For more information about our solutions, you can contact us and request a demo.
Once we receive your form, we will contact you for appropriate demo dates.
You can contact us by filling out the form below.